SCHEMBL24371395

SCHEMBL24371395

CCOc1cc(C(C)C)cc(OCC)c1C(C)=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.49
CYP3A4 P08684 1/20 0.49
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
CREBBP Q92793 1/20 0.42
BCHE P06276 4/20 0.42
ACHE P22303 4/20 0.42
CA9 Q16790 2/20 0.42
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RARG P13631 1/20 0.38
RXRA P19793 1/20 0.38
PPARG P37231 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22946243 0.90 BCHE (0.45) TSHRCYP3A4FABP3FABP4CREBBP
SCHEMBL29633554 0.86 TSHR (0.46) TSHRCYP3A4CREBBPCA9KDM4E
SCHEMBL27022164 0.86 CYP3A4 (0.41) TSHRCYP3A4FABP3FABP4CREBBP
SCHEMBL24488940 0.85 CYP3A4 (0.40) TSHRCYP3A4FABP3FABP4CREBBP
SCHEMBL22946115 0.84 ACHE (0.40) TSHRCYP3A4FABP3FABP4CREBBP
SCHEMBL22945777 0.79 CREBBP (0.54) TSHRCYP3A4CREBBPCA9KDM4E
SCHEMBL22946040 0.79 TSHR (0.53) TSHRCYP3A4CREBBPCA9KDM4E
SCHEMBL27016335 0.79 CYP3A4 (0.50) TSHRCYP3A4FABP3FABP4CA9
SCHEMBL24371397 0.78 CYP3A4 (0.57) TSHRCYP3A4CREBBPBCHEACHE
SCHEMBL24488712 0.78 TSHR (0.52) TSHRCYP3A4CREBBPCA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
WO-2022083703-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 TSHR 925/4885CYP3A4 3547/4885FABP3 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.